- Oops!Something went wrong.Please try again later.
Welcome to the Cannabis Countdown. In this week’s rendition, we’ll recap and countdown the top 10 Marijuana and Psychedelic stock news stories for the week of April 20th – 26th, 2020.
Without further ado, let’s get started.
* Yahoo Finance readers, please click here to view full article.
The federal government of both the U.S. and Canada have green-lit the burgeoning Psychedelics industry while also placing extremely high barriers to entry. Investors looking to get involved in the world of Psychedelic Medicine should take a close look at the two companies leading the emerging sector forward.
READ FULL PSYCHEDELIC MEDICINE ARTICLE
9. 3 Pot Stocks That Posted Profits in the Past Year
It’s Rare to Find a Cannabis Company That Can Stay Out of the Red
READ FULL POT STOCKS ARTICLE
8. MindMed’s New Psychedelics Invention Could Make ‘Bad Trips’ a Thing of the Past
MindMed Has Developed New Technology That Could Help Shorten or Stop an Unwanted LSD Trip
MindMed (OTC: MMEDF) announced that it has discovered a new technology that the company says could help shorten or even stop the effects of an undesired LSD trip. MindMed’s ‘LSD Neutralizer’ could help the industry reduce the stigma and fear associated with Psychedelics By eliminating ‘Bad Trip’ experiences.
READ FULL MINDMED ARTICLE
7. Aurora Cannabis: A Trio of Writedowns Likely Awaits
The Most Popular Pot Stock’s Balance Sheet Needs a Lot of Work
Unfortunately, Aurora Cannabis (NYSE: ACB) has been a veritable dumpster fire. The company continues to lose money at an extraordinary pace, and it appears to lack the cash needed to meet its expected liabilities over the coming 12-month period.
READ FULL AURORA CANNABIS ARTICLE
6. Jim Cramer Says Buy Canopy Growth if You Think the Democrats Will Win
Is Canopy a buy? According to at Least One Cheerleader, There is a Set of Circumstances That Could Very Well Propel it Higher
If you are betting on a blue sweep in the upcoming 2020 election, you should be buying Canopy Growth (NYSE: CGC), says Jim Cramer. Here’s why.
READ FULL CRAMER CANOPY ARTICLE
5. Organigram’s Financing is a Good Idea, Says Raymond James
A New Equity Offering By Organigram May Raise a Few Eyebrows But the Move is a Sound One, Says Raymond James Analyst Rahul Sarugaser
Sarugaser recently released a research update on Organigram (NASDAQ: OGI), which saw the analyst maintain his “Outperform 2” rating on OGI stock. Sarugaser believes the company should have an excellent upcoming quarter.
READ FULL ORGANIGRAM ARTICLE
4. Cannabis MSO Hollister Firms Up Deal to Acquire Psychedelics Company AlphaMind
Hollister Biosciences, One of the Hottest Names in Cannabis, is Moving Forward with Another Blockbuster Deal
Hollister Biosciences (OTC: HSTRF) announced that it reached a definitive agreement to acquire AlphaMind Brands, a move that will see the surging multi-state operator (MSO) diversify into the highly promising Psychedelics sector. In late March, Hollister closed its acquisition of Venom Extracts, a leading cannabis extracts firm that generated revenue of $16.4 million and EBITDA of $2.5 million last year.
READ FULL HOLLISTER ARTICLE
3. Will Aphria Flourish in 2020 Despite the Cannabis Industry’s Struggles?
Aphria’s Ongoing Profitability is Impressive
Marijuana stocks are struggling even more than most sectors, but Aphria’s (NYSE: APHA) strong leadership and profitability make it an intriguing bet.
READ FULL APHRIA ARTICLE
2. Champignon Brands Secures Long-Term Supply of Psilocybin Under DEA Schedule 1 License
Champignon’s Lead Investigator and Research Partner, Dr. Michael Hoffer Secured the Psilocybin Supply Under DEA Schedule 1 License
Champignon Brands (OTC: SHRMF) announced it obtained a long-term supply of Psilocybin for the company’s ongoing TBI/PTSD-focused preclinical studies taking place at the University of Miami’s Miller School of Medicine. Champignon’s new Psilocybin source is the same organization that supplied the Psychedelics research studies and trials at Johns Hopkins and Yale University.
READ FULL CHAMPIGNON BRANDS ARTICLE
1. Why Canopy Growth Just Became a Great Buy
The Cannabis Producer Could See a Healthier Bottom Line This Year
There’s reason to be bullish on Canopy Growth (NYSE: CGC), and it’s not only because it’s so much cheaper than it was a year ago. The company’s making moves that should set it up for better results in the future, and that could make the stock a very appealing investment today.
READ FULL CANOPY GROWTH ARTICLE
Photo by Esteban Lopez on Unsplash
See more from Benzinga
© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.